KPV is the tripeptide lysine-proline-valine, the C-terminal end of alpha-MSH. It is studied in cell and mouse models of inflammation, especially colitis.
U.S. status
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention). On October 28, 2026, HHS iss…
GHK-Cu is the copper complex of the tripeptide glycyl-histidyl-lysine. It is widely studied in skin and wound models and used in topical cosmetics.
U.S. status
FDA removed injectable GHK-Cu from its Category 2 compounding list in April 2026 and scheduled it for advisory-committee review before the end of February 2027. It is not covered by the October 2026 HHS interim policy.
Reference identifiers
KPV + GHK-Cu identity data
Database identity describes the reference substance, not any specific material or lot.
Primary name
KPV + GHK-Cu
Also indexed as
Two-component source-list group
Components
KPV + GHK-Cu
Official & primary sources
Regulatory and database records
Citation does not imply an Elevated Pharma partnership or endorsement.